# Dejan Micić

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dejan-micic/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,607 |
| Field | Inflammatory Bowel Disease |
| h-index | 31 |
| i10-index | 78 |
| Last Known Institution | Loyola University Medical Center |
| OpenAlex ID | https://openalex.org/A5044048621 |
| ORCID iD | 0000-0003-2864-1670 |
| Works | 253 |

## Researcher papers

- [Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis](https://scholariq.org/papers/prevalence-and-clinical-outcomes-of-covid-19-in-patients-with-autoimmune/)
- [Clostridium difficile Ribotype Does Not Predict Severe Infection](https://scholariq.org/papers/clostridium-difficile-ribotype-does-not-predict-severe-infection/)
- [Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis](https://scholariq.org/papers/risk-of-gastrointestinal-cancers-in-patients-with-cystic-fibrosis-a-systematic/)
- [Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases](https://scholariq.org/papers/predicting-outcomes-to-optimize-disease-management-in-inflammatory-bowel/)
- [<i>Clostridium difficile</i>Ribotype 027: Relationship to Age, Detectability of Toxins A or B in Stool With Rapid Testing, Severe Infection, and Mortality](https://scholariq.org/papers/i-clostridium-difficile-i-ribotype-027-relationship-to-age-detectability-of/)
- [Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseases](https://scholariq.org/papers/systematic-review-with-meta-analysis-the-efficacy-and-safety-of-ct-p13-a/)
- [Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease](https://scholariq.org/papers/safety-and-efficacy-of-combination-treatment-with-calcineurin-inhibitors-and/)
- [Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease](https://scholariq.org/papers/vedolizumab-in-patients-with-concurrent-primary-sclerosing-cholangitis-and/)
- [Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis](https://scholariq.org/papers/outcome-of-pregnancy-and-neonatal-complications-with-anti-tumor-necrosis-factor/)
- [The Systemic Inflammatory Response to Clostridium difficile Infection](https://scholariq.org/papers/the-systemic-inflammatory-response-to-clostridium-difficile-infection/)
- [Long‐Term Outcomes With Teduglutide From a Single Center](https://scholariq.org/papers/long-term-outcomes-with-teduglutide-from-a-single-center/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Clostridium difficile and Clostridium perfringens research](https://scholariq.org/topics/clostridium-difficile-and-clostridium-perfringens-research/)
- [Clinical Nutrition and Gastroenterology](https://scholariq.org/topics/clinical-nutrition-and-gastroenterology/)
- [Gastrointestinal Bleeding Diagnosis and Treatment](https://scholariq.org/topics/gastrointestinal-bleeding-diagnosis-and-treatment/)

## Researcher university

- [Loyola University Medical Center](https://scholariq.org/institutions/loyola-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.